Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 629 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: quinolone Clear all

Conditions: Hepatitis C
Interventions: BMS-791325, Moxifloxacin, Placebo matching BMS-791325; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Tuberculosis
Interventions: rifapentine, rifapentine and moxifloxacin, control; Drug
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 12 Years and older
Enrollment: 2,516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 5
States / cities: San Francisco, California • New York, New York • Fort Worth, Texas + 2 more

Conditions: Healthy
Interventions: Bilastine, Bilastine & Ketoconazole, Moxifloxacin, Placebo; Drug
Lead sponsor: Faes Farma, S.A.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Major Depressive Disorder
Interventions: Antidepressant + Aripiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,002 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 58
States / cities: Mesa, Arizona • Peoria, Arizona • Beverly Hills, California + 55 more

Conditions: Functional Dyspepsia
Interventions: YM443, Placebo, Moxifloxacin; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Infection, Human Immunodeficiency Virus
Interventions: Ortho-Cyclen, Dolutegravir, Placebo; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Cardiovascular Diseases, Dysphagia
Interventions: Fiberoptic Endoscopic Evaluation of Swallowing, Simultaneous FEES and Videofluoroscopy instrumental swallowing exam, Videofluoroscopy instrumental swallowing exam (VFSS), Voluntary Cough Peak Expiratory Flow (PEF) Testing, Reflex Cough Screen, Lingual Pressure Testing, Speech Testing; Diagnostic Test · Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 90 Years
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Gainesville, Florida • Columbus, Ohio

Conditions: Electrocardiogram Repolarisation Abnormality, Gonococcal Infection
Interventions: AZD0914, Moxifloxacin, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Psychotic Disorders
Interventions: Aripiprazole or Perphenazine, Metformin, Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 8 Years to 19 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 4
States / cities: Baltimore, Maryland • Glen Oaks, New York • Chapel Hill, North Carolina

Conditions: Schizophrenia
Interventions: aripiprazole IM depot, aripiprazole tablets; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 7
States / cities: Cerritos, California • Garden Grove, California • Glendale, California + 4 more

Conditions: Diabetic Foot Ulcers
Interventions: ofloxacin, MSI-78; Drug
Lead sponsor: Abeona Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 1996
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Abnormalities, Cardiovascular
Interventions: Volanesorsen, Moxifloxacin, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Schizophrenia
Interventions: PF-00217830, Placebo, Aripiprazole; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 8
States / cities: Garden Grove, California • Torrance, California • Washington D.C., District of Columbia + 5 more

Conditions: Bipolar Disorder
Interventions: risperidone, aripiprazole; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 7 Years to 12 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Tuberculosis
Interventions: Gatifloxacin, Isoniazid, Levofloxacin, Linezolid, Moxifloxacin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Schizophrenia, Sensory Gating
Interventions: Aripiprzole; Drug
Lead sponsor: New Mexico VA Healthcare System; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: OPC-34712 (4mg), Moxifloxacin, OPC-34712 (12mg), Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 8
States / cities: Long Beach, California • San Diego, California • Fort Lauderdale, Florida + 5 more

Conditions: Psychotic Depression
Interventions: Aripiprazole; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Urinary Tract Infection
Interventions: Cefpodoxime, Ciprofloxacin; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 2
States / cities: Miami, Florida • Seattle, Washington

Conditions: Schizophrenia
Interventions: Aripiprazole IM Depot; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,081 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 96
States / cities: Chandler, Arizona • Anaheim, California • Cerritos, California + 78 more

Conditions: Bipolar Disorder
Interventions: Aripiprazole; Drug
Lead sponsor: Cambridge Health Alliance; Other
Eligibility: 18 Years to 64 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Irritability Associated With Autistic Disorder
Interventions: Aripiprazole, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 38
States / cities: Dothan, Alabama • Phoenix, Arizona • Costa Mesa, California + 33 more

Conditions: Bacterial Conjunctivitis
Interventions: Gatifloxacin 0.5% eye drops, placebo eye drops; Drug
Lead sponsor: Allergan; Industry
Eligibility: 1 Year and older
Enrollment: 859 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Downey, California

Conditions: QT Interval
Interventions: Telotristat etiprate, Placebo, Moxifloxacin; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2014
U.S. locations: 1
States / cities: Evansville, Indiana

Search by objective public record fields.

Study to Determine the Effect of BMS-791325 on the ECG QTcF Interval in Healthy Subjects

TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens

A Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic (ECG) Effects of Bilastine

A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder

A Study to Evaluate the Effect of Repeat Oral Doses of YM443 on Cardiac Repolarization in Healthy Adults

Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and Ethinylestradiol

Clinical Markers of Dysphagia in Cardiac Surgical Patients

Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects

Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics

A Multiple Dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot

MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers

A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers

Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia

Side Effect Study of Antipsychotic Medicines to Treat Childhood Bipolar Disorder

Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis

Remediation of Schizophrenia Sensory Gating Deficit With Aripiprazole

Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder

The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression

Cefpodoxime vs Ciprofloxacin for Acute Cystitis

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

Aripiprazole in the Treatment of Bipolar Depression

Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder

A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis

A Thorough QT Study of Telotristat Etiprate